Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer

Caio M. Rocha Lima, Soley Bayraktar, Aurea M. Flores, Jessica MacIntyre, Alberto Montero, Joaquina C. Baranda, John Wallmark, Chia Portera, Rajiv Raja, Howard Stern, Stephanie Royer-Joo, Lukas C. Amler

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

In this multicenter phase Ib study, drozitumab was given in combination with the mFOLFOX6 regimen and bevacizumab in patients with previously untreated, locally advanced recurrent or metastatic colorectal cancer on day 1 of every 14-day cycle. Nine patients were treated at 2 different cohort dose levels of drozitumab. No dose-limiting toxicities occurred at either dose level and the maximum tolerated dose was not reached. Two patients had a partial response of 4.93 and 4.96 months duration. Cohort 2 dose level is the recommended starting dose level for future trials.

Original languageEnglish
Pages (from-to)727-731
Number of pages5
JournalCancer Investigation
Volume30
Issue number10
DOIs
StatePublished - Dec 1 2012

Fingerprint

Colorectal Neoplasms
Maximum Tolerated Dose
Bevacizumab
drozitumab

Keywords

  • Apo2 ligand
  • Apoptosis
  • Drozitumab
  • Efficacy
  • Metastatic colorectal cancer
  • Toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rocha Lima, C. M., Bayraktar, S., Flores, A. M., MacIntyre, J., Montero, A., Baranda, J. C., ... Amler, L. C. (2012). Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Cancer Investigation, 30(10), 727-731. https://doi.org/10.3109/07357907.2012.732163

Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. / Rocha Lima, Caio M.; Bayraktar, Soley; Flores, Aurea M.; MacIntyre, Jessica; Montero, Alberto; Baranda, Joaquina C.; Wallmark, John; Portera, Chia; Raja, Rajiv; Stern, Howard; Royer-Joo, Stephanie; Amler, Lukas C.

In: Cancer Investigation, Vol. 30, No. 10, 01.12.2012, p. 727-731.

Research output: Contribution to journalArticle

Rocha Lima, CM, Bayraktar, S, Flores, AM, MacIntyre, J, Montero, A, Baranda, JC, Wallmark, J, Portera, C, Raja, R, Stern, H, Royer-Joo, S & Amler, LC 2012, 'Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer', Cancer Investigation, vol. 30, no. 10, pp. 727-731. https://doi.org/10.3109/07357907.2012.732163
Rocha Lima, Caio M. ; Bayraktar, Soley ; Flores, Aurea M. ; MacIntyre, Jessica ; Montero, Alberto ; Baranda, Joaquina C. ; Wallmark, John ; Portera, Chia ; Raja, Rajiv ; Stern, Howard ; Royer-Joo, Stephanie ; Amler, Lukas C. / Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. In: Cancer Investigation. 2012 ; Vol. 30, No. 10. pp. 727-731.
@article{08280bf28a794082bf1f2c7c6c95f923,
title = "Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer",
abstract = "In this multicenter phase Ib study, drozitumab was given in combination with the mFOLFOX6 regimen and bevacizumab in patients with previously untreated, locally advanced recurrent or metastatic colorectal cancer on day 1 of every 14-day cycle. Nine patients were treated at 2 different cohort dose levels of drozitumab. No dose-limiting toxicities occurred at either dose level and the maximum tolerated dose was not reached. Two patients had a partial response of 4.93 and 4.96 months duration. Cohort 2 dose level is the recommended starting dose level for future trials.",
keywords = "Apo2 ligand, Apoptosis, Drozitumab, Efficacy, Metastatic colorectal cancer, Toxicity",
author = "{Rocha Lima}, {Caio M.} and Soley Bayraktar and Flores, {Aurea M.} and Jessica MacIntyre and Alberto Montero and Baranda, {Joaquina C.} and John Wallmark and Chia Portera and Rajiv Raja and Howard Stern and Stephanie Royer-Joo and Amler, {Lukas C.}",
year = "2012",
month = "12",
day = "1",
doi = "10.3109/07357907.2012.732163",
language = "English",
volume = "30",
pages = "727--731",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer

AU - Rocha Lima, Caio M.

AU - Bayraktar, Soley

AU - Flores, Aurea M.

AU - MacIntyre, Jessica

AU - Montero, Alberto

AU - Baranda, Joaquina C.

AU - Wallmark, John

AU - Portera, Chia

AU - Raja, Rajiv

AU - Stern, Howard

AU - Royer-Joo, Stephanie

AU - Amler, Lukas C.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - In this multicenter phase Ib study, drozitumab was given in combination with the mFOLFOX6 regimen and bevacizumab in patients with previously untreated, locally advanced recurrent or metastatic colorectal cancer on day 1 of every 14-day cycle. Nine patients were treated at 2 different cohort dose levels of drozitumab. No dose-limiting toxicities occurred at either dose level and the maximum tolerated dose was not reached. Two patients had a partial response of 4.93 and 4.96 months duration. Cohort 2 dose level is the recommended starting dose level for future trials.

AB - In this multicenter phase Ib study, drozitumab was given in combination with the mFOLFOX6 regimen and bevacizumab in patients with previously untreated, locally advanced recurrent or metastatic colorectal cancer on day 1 of every 14-day cycle. Nine patients were treated at 2 different cohort dose levels of drozitumab. No dose-limiting toxicities occurred at either dose level and the maximum tolerated dose was not reached. Two patients had a partial response of 4.93 and 4.96 months duration. Cohort 2 dose level is the recommended starting dose level for future trials.

KW - Apo2 ligand

KW - Apoptosis

KW - Drozitumab

KW - Efficacy

KW - Metastatic colorectal cancer

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84870686976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870686976&partnerID=8YFLogxK

U2 - 10.3109/07357907.2012.732163

DO - 10.3109/07357907.2012.732163

M3 - Article

C2 - 23061802

AN - SCOPUS:84870686976

VL - 30

SP - 727

EP - 731

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 10

ER -